Navigation Links
All Intravascular Devices Pose Risk of Bloodstream Infection to Patients

All types of intravascular devices (IVDs) pose a risk of bloodstream infection to exposed hospitalized adult patients//, finds a study published in the September issue of Mayo Clinic Proceedings. What’s more, IVDs have become the leading cause of bloodstream infections in health care settings in the United States and worldwide. An IVD is described as any device that allows access to the bloodstream, but typically a catheter.

As many as 500,000 IVD-related bloodstream infections occur in the United States each year and lead to increased morbidity and prolonged hospital stays, from 10 to 20 days, costing $4,000 to $56,000 per episode. Catheter- or device-related bloodstream infections are widely considered the most preventable class of infections occurring in hospitals.

Authors of the IVD article in Mayo’s medical journal extracted data from 200 prospective studies to examine the risk of IVD-related bloodstream infections associated with each type of IVD. Lead author Dennis Maki, M.D., a researcher and infectious disease and critical care specialist at the University of Wisconsin Hospital and Clinics in Madison, says the findings offer “hard data” that IVDs pose a risk to all recipients.

“We thought this analysis might provide a unique opportunity to wave the flag and convince both health care workers and patients that all types of IVDs pose a risk,” Dr. Maki says. “Clinicians and quality assurance experts need to understand that these risks are significant and are often greater than they might think.”

The use of specialized IVDs for long-term or indefinite vascular access has dramatically increased in recent years in hospital and especially outpatient settings, but attention to reducing incidence of bloodstream infections has focused almost exclusively on patients with short-term central venous catheters in intensive care units, Dr. Maki says. In the last decade, virtually all progress in control of IVD-related bloodstr eam infections has been restricted to this relatively small fraction of hospitalized patients.

The same strategies need to be implemented on a far wider scale, argue the researchers, to make IVDs safer for all hospitalized patients, as well as outpatients who have IVDs.

Guidelines -- such as those published by the Centers for Disease Control’s (CDC) Hospital Infection Control Practices Advisory Committee in 2002 -- exist for prevention of IVD-related bloodstream infections and need to be adapted more widely by health care providers to ensure safer IVD use. Reduced bloodstream infections will follow, predicts Dr. Maki.

The article’s authors also urge wider use of novel IVD technologies designed to reduce IVD-related bloodstream infections. In an accompanying editorial, David Snydman, M.D., of Tufts-New England Medical Center, also cites advancing technology as a promising means for reducing IVD-related bloodstream infections.

“Technology holds far more promise for reducing risk than behavioral modification,” Dr. Maki says. “We believe that it holds the greatest promise. In our paper, we point up a number of IVD technologies that have been proven to be effective, but, as yet, inexplicably, aren’t widely used.”

Although consumers may be surprised to learn that all IVDs carry a risk of bloodstream infection, Dr. Maki advises them to become better informed, not alarmed. Vascular access is absolutely essential to today’s health care and in many cases is lifesaving, he says. But if an IVD insertion is scheduled, patients should feel comfortable asking their health care providers what measures will be taken to minimize their risk of bloodstream infection, Dr. Maki says.


Related medicine news :

1. Injection supports Heart Devices
2. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
3. Making MRIs Safe for Patients With Implantable Heart Devices
4. Scientists Concerned Over Increasing Malfunction Of Heart Devices
5. Anti-Microbial Coating For Use Over Biomedical Devices Developed
6. Scrutiny Sought For Reused Devices in U.S.
7. Sleep Apnea Can Be Treated With Oral Devices
8. Sensing Devices to Measure Sleep In the Pipeline
9. Current Cooling Devices Ineffective in Preventing Brain Injury
10. Computer Assisted Neuro-Rehabilitation Devices Way of the Future
11. Epilepsy Treated with Implanted Devices
Post Your Comments:

(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a ... and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves ... a significant amount of time in Sweden since joining PartnerTech based in Malmo, ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... och UPPSALA, Sverige, December 1, 2015 ... International Breast Cancer Study Group (IBCSG, ... Bryssel) att ingå i en klinisk studie av ... --> --> Studien, med namn ... behandlas med anti-hormonella läkemedel i kombination med palbociclib, ...
(Date:11/30/2015)... Minn. and BASEL, Switzerland ... Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary ... further development of a novel, oral small molecule inhibitor ... that may be effective in the treatment of inflammatory ... clinical development. --> --> ...
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
Breaking Medicine Technology: